Trial Profile
Evolution of Gray Matter Atrophy Over 4 Years in Observational Study of Early IFNbeta-1a I.M. Treatment in High Risk Subjects After Clinically Isolated Syndrome (SET Substudy)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Jun 2015
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Demyelinating disorders
- Focus Therapeutic Use
- Acronyms SET Substudy
- 08 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 May 2012 New trial record